Market news
SAN JOSE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s management team will participate in the upcoming September conferences. 10th Annual Best Ideas Growth (BIG10) Conference hosted by Lake Street Capital MarketsDate: Thursday, September 10, 2026 Format: 1x1 MeetingsLocation: New York, NY H.C. Wainwright 28th Annual Global Investment C
Rani Therapeutics (NASDAQ:RANI) outlined its strategy to expand the use of its RaniPill oral biologic-delivery platform through a mix of technology partnerships, selectively licensed product programs and investments in manufacturing capacity. Chief Executive Officer Talat Imran described the clinic
~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~ ~ Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing ~ ~ Completed a $20 million registered direct offering ~ ~ Expanded obesity pipeline through new research and development collaboration with PegBio to explore oral delivery of novel o
Detailed price information for Rani Therapeutics Holdings Inc Cl A (RANI-Q) from The Globe and Mail including charting and trades.
~ Former Chief Financial Officer of Arcellx Brings Deep Capital Markets and Biotech Financial Leadership Experience ~SAN JOSE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced the appointment of Michelle Gilson to its Board of Directors. Ms. Gilson will serve as Chair of the Audit Committee. "The combination of deep capital markets expertise and hands-on finan
Detailed price information for Rani Therapeutics Holdings Inc Cl A (RANI-Q) from The Globe and Mail including charting and trades.
SAN JOSE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported that it granted an equity award in the form of a stock option to purchase 2,000,000 shares of Rani Class A common stock to Nicholas Maestas, Rani’s new Chief Financial Officer, as an inducement material to his acceptance of employment with Ran
Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.
RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild and consistent with the GLP-1/GLP-2 agonist class of therapeuticsPhase 1a study expanded with an additional cohort to further define the oral-to-subcutaneous pharmacokinetic relationship ahead of a planned Phase 1b repeat-dose study in patients with obesity SAN JOSE, Calif., July 15, 2026 (GLOBE NEWS
Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.
~ Collaboration will leverage the RaniPill® platform to explore oral delivery of PegBio's proprietary portfolio of novel obesity and metabolic disease...
This is the newest page. Registered accounts read further back.